Arcutis Biotherapeutics, Inc. (ARQT) shareholders
Close on Nov 17, 2026Market cap $3.44BP/E 124.2Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 17,751,435 | 14.10% | 13G (passive) amendment | Sep 30, 2026 |
| Aaron Cowen Joint filing with Suvretta Capital Management, LLC (9.99%), Averill Master Fund, Ltd. (9.10%) | 9,534,837 | 9.99% | 13G (passive) amendment | Dec 31, 2023 |
| Patrick J. Heron Joint filing with James N. Topper (7.40%), Fhm Life Sciences Viii, L.L.C. (7.40%) and 2 more | 8,943,712 | 7.50% | 13D (active) amendment | Aug 18, 2025 |
| Rubric Capital Management LP Joint filing with David Rosen (6.75%) | 8,271,577 | 6.75% | 13G (passive) amendment | Dec 31, 2025 |
| State Street Corporation | 7,718,628 | 6.10% | 13G (passive) | Sep 30, 2026 |
| Polar Capital Holdings Plc Joint filing with Polar Capital LLP (5.65%), Polar Capital Funds PLC - Biotechnology Fund (5.06%) | 6,706,475 | 5.65% | 13G (passive) amendment | Mar 31, 2025 |
| Polar Capital LLP Joint filing with Polar Capital Holdings Plc (5.28%) | 6,606,945 | 5.28% | 13G (passive) | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ARQT | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | 12,437,000 | 9.89% | $326.10M | +110,000 | 5.96% |
| BlackRock, Inc. | 10,545,466 | 8.39% | $276.50M | +1,345,055 | 0.00% |
| Frazier Life Sciences Management, L.P. | 9,874,511 | 7.86% | $258.91M | – | 5.64% |
| Rubric Capital Management LP | 8,271,577 | 6.58% | $216.88M | – | 1.99% |
| Polar Capital Holdings Plc | 6,606,945 | 5.26% | $173.23M | +940,005 | 0.41% |
| State Street Corp | 5,822,840 | 4.63% | $152.67M | −473,357 | 0.00% |
| Vanguard Capital Management LLC | 4,988,756 | 3.97% | $130.81M | +117,220 | 0.00% |
| Morgan Stanley | 4,451,014 | 3.54% | $116.71M | +232,083 | 0.01% |
| Jennison Associates LLC | 4,219,058 | 3.36% | $110.62M | −761,712 | 0.07% |
| D. E. Shaw & Co., Inc. | 3,949,609 | 3.14% | $103.56M | +1,453,387 | 0.05% |
| UBS Group AG | 3,333,015 | 2.65% | $87.39M | +3,791 | 0.01% |
| Bank Of America Corp /De/ | 2,987,431 | 2.38% | $78.33M | +766,142 | 0.01% |
| Geode Capital Management, LLC | 2,982,446 | 2.37% | $78.21M | −62,860 | 0.00% |
| Vanguard Portfolio Management LLC | 2,429,005 | 1.93% | $63.69M | +474,320 | 0.00% |
| Orbimed Advisors LLC | 2,042,000 | 1.62% | $53.54M | New | 0.99% |
| Franklin Resources Inc | 1,930,982 | 1.54% | $50.63M | −366,961 | 0.01% |
| American Century Companies Inc | 1,925,031 | 1.53% | $50.47M | +461,803 | 0.02% |
| Goldman Sachs Group Inc | 1,668,367 | 1.33% | $43.74M | +65,354 | 0.00% |
| Jupiter Topco LLC | 1,410,435 | 1.12% | $36.99M | New | 0.02% |
| Oberweis Asset Management Inc/ | 1,372,941 | 1.09% | $36.00M | +7,000 | 0.74% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 272 | 131M | 100.0% | 42 / 95 | 100 / 36 | 18M | 18M |
| Q1 2026 | 270 | 133M | 100.0% | 41 / 104 | 88 / 48 | 21M | 10M |
| Q4 2025 | 283 | 129M | 100.0% | 74 / 102 | 78 / 25 | 20M | 17M |
| Q3 2025 | 239 | 126M | 100.0% | 34 / 87 | 84 / 21 | 9M | 10M |
| Q2 2025 | 230 | 127M | 100.0% | 35 / 89 | 67 / 45 | 13M | 11M |
| Q1 2025 | 241 | 126M | 100.0% | 64 / 67 | 80 / 29 | 8M | 11M |
| Q4 2024 | 208 | 129M | 100.0% | 49 / 60 | 65 / 28 | 15M | 16M |
| Q3 2024 | 188 | 130M | 100.0% | 34 / 72 | 48 / 31 | 20M | 10M |
| Q2 2024 | 186 | 128M | 100.0% | 47 / 59 | 55 / 29 | 21M | 27M |
| Q1 2024 | 168 | 134M | 100.0% | 59 / 52 | 40 / 23 | 43M | 16M |
| Q4 2023 | 133 | 107M | 85.5% | 40 / 51 | 24 / 40 | 60M | 20M |
| Q3 2023 | 134 | 67M | 53.4% | 18 / 53 | 38 / 18 | 3M | 6M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
213 funds held ARQT in Q2 2026, 50% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ARQT | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3,564,957 | 2.84% | $93.47M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 2,937,192 | 2.34% | $77.01M | 0.09% | Jun 30, 2026 |
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 2,914,129 | 2.32% | $76.41M | 0.71% | Jun 30, 2026 |
| Small Cap Growth Fund | 1,466,411 | 1.17% | $39.39M | 0.71% | Jul 31, 2026 |
| PGIM Jennison Small Company Fund | 1,386,237 | 1.10% | $36.35M | 1.04% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,308,312 | 1.04% | $34.30M | 0.04% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,250,551 | 0.99% | $33.59M | 0.10% | Jul 31, 2026 |
| Oberweis Small-Cap Opportunities Fund | 1,211,800 | 0.96% | $31.77M | 1.12% | Jun 30, 2026 |
| iShares Russell 2000 Growth ETF | 1,056,318 | 0.84% | $27.70M | 0.18% | Jun 30, 2026 |
| Baron Discovery Fund | 867,400 | 0.69% | $22.74M | 1.24% | Jun 30, 2026 |
| iShares Biotechnology ETF | 782,595 | 0.62% | $20.52M | 0.23% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 576,471 | 0.46% | $12.37M | 0.03% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 565,357 | 0.45% | $12.13M | 0.07% | May 31, 2026 |
| Vanguard Explorer Fund | 561,183 | 0.45% | $15.07M | 0.07% | Jul 31, 2026 |
| Schwab U.S. Small-Cap ETF | 534,058 | 0.42% | $11.46M | 0.05% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Todd Watanabe | See Remarks, Director | 895,140 | 0.71% | Nov 4, 2026 |
| Patrick Burnett | EVP, Chief Medical Officer | 116,649 | 0.09% | Nov 4, 2026 |
| Robert Lisicki | EVP, Chief Commercial Officer | 55,000 | 0.04% | Nov 4, 2026 |
| Masaru Matsuda | EVP, Chief Legal Officer | 111,289 | 0.09% | Nov 4, 2026 |
| Latha Vairavan | SVP Chief Financial Officer | 85,978 | 0.07% | May 13, 2026 |
| Larry Todd Edwards | See Remarks | 175,178 | 0.14% | Mar 3, 2026 |
| David Joseph Topper | Chief Financial Officer | 182,774 | 0.15% | Apr 3, 2025 |
| Robert A. Scott | Director | 20,342 | 0.02% | Nov 4, 2026 |
| Howard G. Welgus | Director | 60,198 | 0.05% | Oct 19, 2026 |
| Terrie Curran | Director | 23,526 | 0.02% | Aug 28, 2026 |
| Christopher Peetz | Director | 191,815 | 0.15% | Jul 17, 2026 |
| Sue-Jean Lin | Director | 27,567 | 0.02% | Jun 17, 2026 |
| Patrick J. Heron | Director | 59,661 | 0.05% | Jun 12, 2026 |
| Keith R. Leonard | Director | 29,651 | 0.02% | Jun 9, 2026 |
| Halley E. Gilbert | Director | 27,901 | 0.02% | Jun 9, 2026 |
| Neha Krishnamohan | Director | 27,901 | 0.02% | Jun 9, 2026 |
| Amit Munshi | Director | 9,799 | 0.01% | Jun 9, 2026 |
| Bhaskar Chaudhuri | Director | 917,807 | 0.73% | Jun 16, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Masaru Matsuda EVP, Chief Legal Officer | Nov 4, 2026 | Sale(10b5-1 plan) | −40,000 | $34.32 | $1.37M | 111,289 |
| Masaru Matsuda EVP, Chief Legal Officer | Nov 4, 2026 | Option exercise | +40,000 | $3.64 | $145.60K | 151,289 |
| Masaru Matsuda EVP, Chief Legal Officer | Nov 2, 2026 | Sale(10b5-1 plan) | −1,219 | $31.86 | $38.84K | 111,289 |
| Patrick Burnett EVP, Chief Medical Officer | Nov 2, 2026 | Sale | −943 | $31.86 | $30.05K | 116,649 |
| Todd Watanabe See Remarks, Director | Nov 2, 2026 | Sale | −4,377 | $31.86 | $139.47K | 712,826 |
| Robert A. Scott Director | Oct 23, 2026 | Award | +2,819 | – | – | 2,819 |
| Howard G. Welgus Director | Oct 15, 2026 | Sale(10b5-1 plan) | −4,728 | $26.93 | $127.33K | 35,207 |
| Howard G. Welgus Director | Oct 15, 2026 | Option exercise | +2,254 | $8.63 | $19.45K | 39,935 |
| Howard G. Welgus Director | Oct 15, 2026 | Option exercise | +1,018 | $7.51 | $7.65K | 37,681 |
| Howard G. Welgus Director | Oct 15, 2026 | Option exercise | +822 | $6.52 | $5.36K | 36,663 |
| Masaru Matsuda See Remarks | Sep 16, 2026 | Sale(10b5-1 plan) | −3,674 | $25.00 | $91.85K | 112,508 |
| Howard G. Welgus Director | Sep 15, 2026 | Option exercise | +1,019 | $7.51 | $7.65K | 38,316 |
| Howard G. Welgus Director | Sep 15, 2026 | Option exercise | +2,255 | $8.63 | $19.46K | 40,571 |
| Howard G. Welgus Director | Sep 15, 2026 | Sale(10b5-1 plan) | −4,730 | $24.18 | $114.37K | 35,841 |
| Howard G. Welgus Director | Sep 15, 2026 | Option exercise | +822 | $6.52 | $5.36K | 37,297 |
| Masaru Matsuda See Remarks | Sep 8, 2026 | Sale(10b5-1 plan) | −9,989 | $25.03 | $250.02K | 116,182 |
| Terrie Curran Director | Aug 27, 2026 | Sale | −27,052 | $25.03 | $677.11K | 23,526 |
| Terrie Curran Director | Aug 27, 2026 | Option exercise | +11,148 | $7.51 | $83.72K | 34,674 |
| Terrie Curran Director | Aug 27, 2026 | Sale | −11,148 | $25.03 | $279.03K | 23,526 |
| Terrie Curran Director | Aug 27, 2026 | Option exercise | +27,052 | $8.63 | $233.46K | 50,578 |
| Terrie Curran Director | Aug 20, 2026 | Sale | −1,072 | $26.04 | $27.91K | 23,526 |
| Terrie Curran Director | Aug 20, 2026 | Option exercise | +1,072 | $7.51 | $8.05K | 24,598 |
| Patrick Burnett See Remarks | Aug 19, 2026 | Sale | −1,697 | $27.00 | $45.82K | 117,592 |
| Howard G. Welgus Director | Aug 17, 2026 | Sale(10b5-1 plan) | −4,730 | $26.18 | $123.83K | 36,475 |
| Howard G. Welgus Director | Aug 17, 2026 | Option exercise | +822 | $6.52 | $5.36K | 37,931 |
| Howard G. Welgus Director | Aug 17, 2026 | Option exercise | +1,019 | $7.51 | $7.65K | 38,950 |
| Howard G. Welgus Director | Aug 17, 2026 | Option exercise | +2,255 | $8.63 | $19.46K | 41,205 |
| Patrick Burnett See Remarks | Aug 12, 2026 | Option exercise | +6,700 | $3.64 | $24.39K | 125,989 |
| Patrick Burnett See Remarks | Aug 12, 2026 | Sale | −6,700 | $26.08 | $174.74K | 119,289 |
| Patrick Burnett See Remarks | Aug 11, 2026 | Option exercise | +8,300 | $3.64 | $30.21K | 127,589 |
| Patrick Burnett See Remarks | Aug 11, 2026 | Sale | −8,300 | $26.52 | $220.12K | 119,289 |
| Patrick Burnett See Remarks | Aug 3, 2026 | Sale(10b5-1 plan) | −955 | $26.12 | $24.94K | 119,289 |
| Masaru Matsuda See Remarks | Aug 3, 2026 | Sale(10b5-1 plan) | −1,230 | $26.12 | $32.13K | 126,171 |
| Todd Watanabe See Remarks, Director | Aug 3, 2026 | Sale(10b5-1 plan) | −4,375 | $26.12 | $114.28K | 717,203 |
| Howard G. Welgus Director | Jul 15, 2026 | Option exercise | +822 | $6.52 | $5.36K | 38,565 |
| Howard G. Welgus Director | Jul 15, 2026 | Option exercise | +1,019 | $7.51 | $7.65K | 39,584 |
| Howard G. Welgus Director | Jul 15, 2026 | Sale(10b5-1 plan) | −4,730 | $26.91 | $127.28K | 37,109 |
| Howard G. Welgus Director | Jul 15, 2026 | Option exercise | +2,255 | $8.63 | $19.46K | 41,839 |
| Christopher Peetz Director | Jul 15, 2026 | Award | +4,315 | – | – | 4,315 |
| Howard G. Welgus Director | Jun 17, 2026 | Sale(10b5-1 plan) | −635 | $25.67 | $16.30K | 37,743 |
| Sue-Jean Lin Director | Jun 15, 2026 | Sale(10b5-1 plan) | −4,946 | $24.38 | $120.58K | 27,567 |
| Howard G. Welgus Director | Jun 15, 2026 | Sale(10b5-1 plan) | −4,096 | $24.41 | $99.98K | 38,378 |
| Howard G. Welgus Director | Jun 15, 2026 | Option exercise | +822 | $6.52 | $5.36K | 39,200 |
| Howard G. Welgus Director | Jun 15, 2026 | Option exercise | +1,019 | $7.51 | $7.65K | 40,219 |
| Howard G. Welgus Director | Jun 15, 2026 | Option exercise | +2,255 | $8.63 | $19.46K | 42,474 |
| Terrie Curran Director | Jun 5, 2026 | Award | +5,778 | – | – | 23,526 |
| Patrick J. Heron Director | Jun 5, 2026 | Award | +5,778 | – | – | 32,213 |
| Howard G. Welgus Director | Jun 5, 2026 | Award | +5,778 | – | – | 38,378 |
| Amit Munshi Director | Jun 5, 2026 | Award | +5,778 | – | – | 9,799 |
| Keith R. Leonard Director | Jun 5, 2026 | Award | +5,778 | – | – | 27,901 |
| Halley E. Gilbert Director | Jun 5, 2026 | Award | +5,778 | – | – | 27,901 |
| Sue-Jean Lin Director | Jun 5, 2026 | Award | +5,778 | – | – | 32,513 |
| Neha Krishnamohan Director | Jun 5, 2026 | Award | +5,778 | – | – | 27,901 |
| Latha Vairavan SVP Chief Financial Officer | May 11, 2026 | Sale(10b5-1 plan) | −435 | $21.05 | $9.16K | 85,978 |
| Patrick Burnett See Remarks | May 11, 2026 | Sale(10b5-1 plan) | −222 | $21.05 | $4.67K | 120,244 |
| Patrick Burnett See Remarks | May 4, 2026 | Sale(10b5-1 plan) | −684 | $23.61 | $16.15K | 120,466 |
| Latha Vairavan SVP Chief Financial Officer | May 4, 2026 | Sale(10b5-1 plan) | −1,341 | $23.61 | $31.66K | 86,413 |
| Masaru Matsuda See Remarks | May 4, 2026 | Sale(10b5-1 plan) | −884 | $23.61 | $20.87K | 126,689 |
| Masaru Matsuda See Remarks | May 4, 2026 | Sale(10b5-1 plan) | −7,372 | $23.27 | $171.55K | 127,573 |
| Todd Watanabe See Remarks, Director | May 4, 2026 | Sale(10b5-1 plan) | −3,172 | $23.61 | $74.89K | 720,755 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Arcutis Biotherapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 803 shares on Sep 3, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Masaru Matsuda Officer | Nov 4, 2026 | 40,000 | $1.37M | Nov 4, 2026 | Stock Option Exercise |
| Todd Watanabe Officer | Nov 2, 2026 | 4,377 | $139.47K | Nov 2, 2026 | Restricted Stock Vesting |
| Masaru Matsuda Officer | Nov 2, 2026 | 1,219 | $38.84K | Nov 2, 2026 | Restricted Stock Vesting |
| Patrick Burnett Officer | Nov 2, 2026 | 943 | $30.05K | Nov 2, 2026 | Restricted Stock Vesting |
| Larry Todd Edwards Former Officer | Oct 20, 2026 | 60,376 | $1.99M | Oct 20, 2026 | Employee Stock Purchase |
| Howard G. Welgus Director | Oct 15, 2026 | 4,728 | $127.33K | Oct 15, 2026 | Restricted Stock Vesting |
| Larry Todd Edwards Former Officer | Sep 16, 2026 | 341,980 | $8.55M | Sep 16, 2026 | Stock Option Exercise |
| Howard G. Welgus Director | Sep 15, 2026 | 4,730 | $114.37K | Sep 15, 2026 | Restricted Stock Vesting |
| Masaru Matsuda Officer | Sep 8, 2026 | 13,663 | $341.93K | Sep 8, 2026 | Restricted Stock Vesting |
| Terrie Curran Director | Aug 27, 2026 | 38,200 | $956.12K | Aug 27, 2026 | Stock Option Exercise |
| Terrie Curran Director | Aug 20, 2026 | 1,072 | $27.91K | Aug 20, 2026 | Stock Option Exercise |
| Patrick Burnett Officer | Aug 19, 2026 | 1,697 | $45.82K | Aug 19, 2026 | Restricted Stock Vest |
| Howard G. Welgus Director | Aug 17, 2026 | 4,730 | $123.83K | Aug 17, 2026 | Restricted Stock Vesting |
| Patrick Burnett Officer | Aug 11, 2026 | 15,000 | $397.82K | Aug 11, 2026 | Stock Option Exercise |
| Masaru Matsuda Officer | Aug 3, 2026 | 1,230 | $32.12K | Aug 3, 2026 | Restricted Stock Vesting |
Congress trades
6 trades in Arcutis Biotherapeutics reported by 2 members of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Gilbert Cisneros CA31 | Bought | May 29, 2026 | $1K–15K | Jun 8, 2026 |
| Gilbert Cisneros CA31 | Bought | Mar 3, 2026 | $1K–15K | Apr 7, 2026 |
| Gilbert Cisneros CA31 | Sold (part) | Dec 11, 2025 | $1K–15K | Jan 12, 2026 |
| Josh Gottheimer NJ05 · joint account | Sold | Sep 15, 2023 | $1K–15K | Oct 15, 2023 |
| Josh Gottheimer NJ05 · joint account | Bought | Apr 17, 2023 | $1K–15K | May 19, 2023 |
| Josh Gottheimer NJ05 · joint account | Bought | Jun 15, 2022 | $1K–15K | Jul 22, 2022 |
See a number that looks wrong?